1093677-53-2

Upstream product

• 226218-61-7 succinimidyl 2,2-diphenylacetate 
• 16937-91-0 N^ε-(benzyloxycarbonyl)ornithine 
• 1093677-52-1 (R)-Nδ-benzyloxycarbonyl-N-(4-tert-butoxybenzyl)-Nα-(2,2-diphenylacetyl)ornithinamide 

Downstream Products

• 1068148-44-6 (R)-N-(4-tert-butoxybenzyl)-Nω-tert-butoxycarbonyl-Nα-(2,2-diphenylacetyl)argininamide 
• 1311286-04-0 3-((R)-9-amino-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-3,11,18-trioxo-2,8,10,12,17-pentaazahenicos-9-en-21-yl)-2-((1E,3E)-4-(4-(dimethylamino)phenyl)buta-1,3-dienyl)benzo[d]thiazol-3-ium hydrotrifluoroacetate trifluoroacetate 

Relevant academic research and scientific papers

Synthesis and Binding Affinity of Fluorine Containing NG-acyl and -sulfonyl BIBP3226 Derivatives: Ligands for the NPY Y1 Receptor

The neuropeptide Y (NPY) receptors are abundant in a range of tumours hence are a molecular target for tumour imaging and therapy, particularly by the use of radiolabelled molecules. NG-Substituted derivatives of the NPY receptor antagonist, BI

Guanidine-acylguanidine bioisosteric approach in the design of radioligands: Synthesis of a tritium-labeled NG-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist

Synthesis and characterization of (R)-Nα-(2,2- diphenylacetyl)-N-(4-hydroxybenzyl)-Nω-([2,3- 3H]-propanoyl)-argininamide ([3H]-UR-MK114), an easily accessible tritium-labeled NPY Y1 receptor (Y1R) antagonist (KB: 0.8 nM, calcium assay, HEL cells) derived from the (R)-argininamide BIBP 3226, is reported. The radioligand binds with high affinity (KD, saturation: 1.2 nM, kinetic experiments: 1.1 nM, SK-N-MC cells) and selectivity for Y1R over Y2, Y 4, and Y5 receptors. The title compound is a useful pharmacological tool for the determination of Y1R ligand affinities, quantification of Y1R binding sites, and autoradiography.